The co-founders of BioNTech are leaving to start a new mRNA-focused company, while BioNTech will focus on its cancer pipeline; this split aims to add value for shareholders. U.S. Senator Ron Johnson has launched an investigation into the FDA's recent denials of treatments for rare diseases, adding political pressure to the agency. For content creators, these developments highlight shifts in biotech leadership and increased scrutiny of regulatory decisions impacting drug approvals.
Read the full article at STAT News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
17
Comments
Ali NematiWritten by Ali
